GlassScriptPhysician profile
Michael W Brennan
NPI 1619903705
$2,659.36
in general payments reported to CMS, 2019-2025
11 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.67 · 2020: $60.03 · 2021: $163 · 2023: $198 · 2024: $1,906 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,236 · Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,236.23 |
| Food and Beverage | $1,184.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,171.21 | 2021-2025 | Capsurefix Novus Mri Surescan, Micra, Attain Command + Surevalve |
| Edwards Lifesciences Corporation | $211.36 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $71.86 | 2021 | |
| Medtronic Vascular, INC. | $54.95 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $39.25 | 2024 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $26.44 | 2023 | Optimizer |
| Boston Scientific Corporation | $22.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.78 | 2025 | |
| Abiomed | $20.42 | 2025 | |
| Amgen INC. | $11.57 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.18 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.